top of page
Research and Development
At Solgen Pharmaceuticals, our main aim is to get high quality products from lab development to patient as quickly and safely as possible. Our team of highly skilled scientists and regulatory professionals work seamlessly together in order to provide the best possible solutions to current healthcare problems around the world.
​
This page provides an outline of where our current medicines are in development, be this pre-clinical, phase I, II, III or approved. For competitive reasons, certain details are not disclosed. This pipeline information is updated monthly.
Solgen Pharmaceuticals are pleased to announce the development of a novel therapeutic which addresses the unmet need in idiopathic pulmonary fibrosis. Taxifen has the potential to provide better results than seen before through novel targeting of the fibrotic pathway.
​
Last update 25th February 2019
Research and Development: Products
bottom of page